ASX Announcement: 31 July 2026 (Melbourne, Australia)
Optiscan Imaging Ltd (ASX: OIL)

APPENDIX 4C
QUARTERLY ACTIVITIES & CASHFLOW REPORT
QUARTER ENDED 30 JUNE 2026

HIGHLIGHTS

- Optiscan advanced commercialisation of its InSpecta™ device, with launch preparations finalised during the Quarter.
- Soon after Quarter-end, the Company launched InSpecta™ at the American Veterinary Medical Association (AVMA) Convention in Anaheim, California, following lodgment of the device's U.S. FDA dossier last quarter.
- The current Australian Breast Cancer Study utilising the InVue™ and InForm™ platforms advanced beyond the halfway mark, with strong interim imaging results across healthy and malignant breast tissue.
- During the Quarter and after Quarter's end, Optiscan advanced multiple studies supporting the Company's planned U.S. FDA regulatory submissions for InVue™ and InForm™ in the second half of calendar year 2026.
- Optiscan received $2.537m in government grants and tax incentives during the Quarter, comprising of $0.843m CRC-P payment to develop its Edge-AI-enabled gastrointestinal flexible endomicroscope, and a $1.694m R&D tax refund.
- Optiscan invested $1.936m in R&D during the Quarter, advancing clinical and regulatory work for the planned InVue™ and InForm™ U.S. FDA submissions in the second half of calendar year 2026.

Optiscan Imaging Limited (ASX:OIL) ('**Optiscan**' or the '**Company**'), a leader in medical imaging using confocal laser endomicroscopy, is pleased to announce its Appendix 4C Quarterly Cashflow report and business update for the quarter ended 30 June 2026 (the **'Quarter'**). All financial results are in Australian dollars and are unaudited.

CEO COMMENT

Optiscan CEO and Managing Director, Dr Camile Farah, said:

"The multiple development strategy deliverables achieved by Optiscan over the June 2026 quarter built on the strong momentum seen over the first three quarters of the Company's FY26. And all the signs

are there that the strong track record for execution over the past 12 months has extended into the new financial year.

So much has been achieved of late on the regulatory front. The June Quarter saw Optiscan advance the FDA approval process for the InSpecta™ device to the point where it could be launched in the US market – which subsequently happened early in the September 2026 quarter. All this while our team simultaneously undertook the leg work required to meet our target to submit FDA dossiers for InVue™ and InForm™ during the second half of calendar year 2026.

From a product validation angle, the three Australia-based clinical studies involving InVue™ and InForm™ were further advanced in the Quarter, with participant numbers steadily climbing, and early results from these studies already very encouraging. We have, at the same time, progressed our efforts to commence two clinical studies in the U.S. that will provide necessary support for our U.S. FDA InVue™ and InForm™ regulatory submissions, with a Research Agreement signed with the Mayo Clinic for one of these studies in mid-July 2026.

"As we enter FY27, Optiscan is continuing to enjoy clear-cut development momentum with another round of commercial and regulatory milestones set to soon be realised. These include our planned InVue™ and InForm™ FDA submissions, continued commercial progress for InSpecta™, and the expected commencement of the two US-based Mayo Clinic studies. I would like to thank the Optiscan team for their outstanding commitment and contribution throughout FY26, and we look forward to building on this strong foundation in the year ahead."

U.S. FDA SUBMISSION UPDATES

During the Quarter, Optiscan continued progressing its stated plan to complete multiple United States Food and Drug Administration (**'U.S. FDA'**) regulatory submissions across its devices and associated use cases over the course of calendar year 2026, specifically:

U.S. FDA Status	Device	Application
Submitted – Commercially launched	InSpecta™	Veterinary medicine
In progress	InVue™	Precision surgery
In progress	InForm™	Digital pathology

For context, the U.S. FDA regulatory process is a global benchmark for quality, safety and credibility, requiring detailed evidence and documentation to support product claims. Over the past two years, Optiscan has worked with leading regulatory experts to align its submissions with current U.S. FDA requirements.

InSpecta™ - From regulatory submission to commercialisation

Following the successful submission of the InSpecta™ regulatory dossier to the FDA Centre for Veterinary Medicine last quarter (see announcement dated 31 March 2026), Optiscan has continued to progress the commercialisation pathway for this device. Consistent with the U.S. FDA's approach of generally exercising limited regulatory oversight of veterinary devices compared with human medical devices, the Company has advanced launch preparations while continuing to take a prudent and informed approach to regulatory requirements.

Thanks to this measured approach, a strong platform was created for the successful launch of InSpecta™ at the American Veterinary Medical Association (AVMA) Convention in Anaheim, California, which was held subsequent to Quarter's end on 10 July 2026. The launch generated positive engagement with AVMA Convention participants, provided valuable market feedback, and reinforced the potential for future commercial opportunities as InSpecta™ is introduced to the US veterinary market.

U.S. FDA submission preparations for InVue™ and InForm™

During the Quarter, Optiscan maintained a whole-of-company focus on advancing preparations for the planned U.S. FDA regulatory submissions for InVue™ and InForm™. This included coordinated activity across clinical, regulatory, product development, quality and operational teams to ensure the required evidence, documentation and supporting processes continue to progress in line with U.S. FDA requirements.

Optiscan also continued to work closely with experienced regulatory and clinical experts to further strengthen the planned submissions and increase the likelihood of a successful regulatory outcome. Based on progress achieved to date, the Company remains on schedule to lodge the U.S. FDA submissions for InVue™ and InForm™ in the second half of calendar year 2026.

CLINICAL STUDIES PROGRESS, AIDING U.S. FDA SUBMISSIONS

To support the planned U.S. FDA submissions for InVue™ and InForm™ later in calendar year 2026, the Company has partnered with highly regarded clinical and industry collaborators to conduct clinical studies and generate the required clinical evidence. The table below provides a summary of currently active clinical studies as at Quarter end, followed by updates on studies now underway or expected to commence during calendar year 2026.

Clinical Site	Device	Tissue	Participants[1,2]	% Complete
The Royal Melbourne Hospital	InVue™ InForm™	Breast	34 / 50	
St John of God Murdoch Hospital	InVue™ InForm™	Head and Neck	10 / 50	
Australian Clinicalabs	InForm™	Multiple	60	N/A

1. *Table shows progress as of 30 June 2026.*
2. *Participants to date, with the final figure expected to number in the hundreds by the end of the ACL Study.*

1. Breast Clinical Study Advances Past Halfway Mark at the Royal Melbourne Hospital (RMH)

   The first clinical study utilising both the Company's InVue™ (precision surgery) and InForm™ (digital pathology) clinical devices has progressed well during the Quarter, with 34 of the 50 planned cases completed as of 30 June 2026. A second clinical study site at Frances Perry House has accelerated enrolment. Results flowing from the first 25 patients were very positive, with excellent images across healthy and malignant breast tissue, allowing the Company to stay on track for planned U.S. FDA submissions in the second half of calendar year 2026.

2. Head and Neck Cancer Clinical Study Progresses at St John of God Murdoch Hospital (SJOG)

   The Head and Neck Cancer clinical study continued to progress during the Quarter, with 10 patients completing post-operative imaging using InForm™ as at 30 June 2026. Early results from the first five cases have been highly encouraging, supporting ethics approval to accelerate the transition to the second stage of the study from patient 11, which will include imaging with both InForm™ and InVue™. This second stage of the study commenced in mid-July 2026, soon after the Quarter's end. Operational efficiency also continued to improve, supported by the significant learnings gained from the Breast Cancer clinical study at the Royal Melbourne Hospital.

3. Anatomical Pathology Study Progresses at Australian Clinical Labs (ACL)

   The Anatomical Pathology Study continued to build momentum during the Quarter, supported by the appointment of a dedicated staff member in Perth to manage data collection. As at 30 June 2026, the study had generated 60 datasets across a broad range of tissue types and pathologies, including cervix, gallbladder, endometrium, colon, lung, uterus, fallopian tubes, ovary, thyroid, tongue, tonsil, vocal cord, parathyroid, nasal cavity, eye and liver. The study is expected to generate hundreds of imaging datasets, strengthening Optiscan's growing image databank, with a portion of these datasets intended to support the Company's planned InForm™ U.S. FDA submission later in calendar year 2026.

4. US-Based Mayo Clinic Studies Advance Toward Initiation

   In the US, preparations continue with our clinical collaborators at Mayo Clinic, Rochester, Minnesota, for two clinical studies to support U.S. FDA regulatory submissions. The Company received institutional approval for the breast cancer clinical study during the Quarter and institutional approval is underway for the head and neck cancer study. Both studies aim to complete imaging in up to 35 patients each. The clinical team added four new team members over the Quarter, all on-site in Rochester, to facilitate clinical study preparations and site initiation activities. The team has supported a variety of site initiation activities, including the first site initiation visit for the breast study.

5. Gastrointestinal Clinical Study at University Medical Centre Mainz

   The full submission to the University Medical Centre Mainz (Germany) ethics committee received approval during the Quarter, clearing the way for additional clinical study preparation and site initiation activities for an observational imaging study in gastrointestinal (GI) tissues at one of Europe's leading gastroenterology centres.

   The study will collect data from up to 50 patients undergoing upper and lower GI endoscopy procedures and provide images to support ongoing product development activities for the development of the Company's next generation flexible endomicroscope as part of a Cooperative Research Centres Project between Optiscan, Monash University, and Capgemini, funded by the Australian Federal Government.

ADVANCEMENT OF PRODUCT DEVELOPMENT, TESTING AND CERTIFICATION

During the Quarter, Optiscan continued to make strong progress across its product development, testing and certification, with activities increasingly focused on regulatory readiness, clinical deployment and product validation. Key progress included:

a) Continued compliance testing across the device portfolio, with particular focus on InVue™ and InForm™, including electrical safety, cybersecurity, software and electromagnetic compatibility testing to support planned U.S. FDA submissions.

b) Further advancement of regulatory and quality documentation, including completion of core design records and compilation of device history records, supporting a clearer pathway toward regulatory readiness and future manufacturing activities.

c) Successful build of additional InVue™ and InForm™ systems, together with multiple probes, to support active and planned clinical studies across local and overseas sites.

d) Continued progress under the Mayo Clinic collaboration, including development work for a new digital endomicroscopic imaging system for use in robotic surgery, following the two-year milestone of the Company's Know-How Agreement with Mayo Clinic.

SALES PIPELINE AND COMMERCIALISATION EFFORTS

Commercial Readiness and Go-to-Market Preparation

Optiscan continued to make significant progress in advancing its commercialisation strategy during the Quarter, undertaking extensive go-to-market (GTM) planning across its device portfolio, including InSpecta™, InVue™ and InForm™.

A substantial body of work was completed to support future commercial execution, including detailed market segmentation, customer profiling, market opportunity modelling and channel assessment activities for each device. These initiatives have strengthened the Company's understanding of target markets, purchasing drivers, priority customer segments and commercial pathways, providing a robust foundation for future growth.

In parallel, Optiscan developed comprehensive commercial frameworks for each device, including tailored messaging guides, positioning strategies and sales playbooks designed to support consistent market engagement and scalable sales execution. These activities have further refined the Company's value propositions across its portfolio and enhanced commercial readiness ahead of key launch and market expansion initiatives.

InSpecta™ – Preparing for Commercial Launch

During the Quarter, Optiscan progressed preparations for the commercial launch of InSpecta™ in the United States in preparation for U.S. FDA clearance. The Company finalised launch planning for the American Veterinary Medical Association (AVMA) Convention, that took place in California on 10 July 2026, where InSpecta™ was formally introduced to the veterinary market for the first time. Optiscan maintained an exhibition booth presence at the event, providing an opportunity to engage directly with veterinary clinicians, surgeons and practice decision-makers.

In preparation for launch, the Company developed and refined a range of commercial assets to support sales outreach and market engagement activities. This included the completion of product collateral such as the InSpecta™ brochure, alongside supporting sales and marketing materials designed to communicate the device's clinical value proposition and support customer acquisition efforts. Optiscan also continued to build awareness and strengthen relationships within the U.S. veterinary sector, supporting future pipeline development and commercial opportunities.

To further enhance its commercial capabilities, Optiscan completed the implementation of HubSpot as its new customer relationship management (CRM) platform. The platform was leveraged during and following the InSpecta™ launch to support structured sales outreach, lead management, customer engagement tracking and data-driven commercial activities.

ViewnVivo® – Reappraising the Life Sciences Sector

With the Company's clinical portfolio continuing to be advanced, Optiscan has undertaken an ongoing review of the strategic, operational and commercial relevance of its life sciences activities to ensure resources remain aligned with its highest-value growth opportunities. Following this review, the Company is prioritising its expanding clinical portfolio, where it sees significant commercial potential across digital pathology, precision surgery and veterinary medicine. As part of this focus, outbound marketing and business development activities for ViewnVivo® have ceased, and the Company has concluded its distribution arrangements with Biotimes Technology Limited in China.

PUBLIC RELATIONS AND MARKET ENGAGEMENT INITIATIVES

Optiscan continued to expand its public profile and engagement with key stakeholders through a range of public relations, investor relations and thought leadership activities during the Quarter.

During the period, the Company attended the Endeavour Awards as a finalist in multiple categories. While Optiscan was not selected as a winner, being recognised as a finalist represents significant industry recognition and highlights the Company's continued innovation, commercial progress and leadership within the advanced manufacturing and medical technology sectors.

Optiscan CEO, Dr Camile Farah, further strengthened Optiscan's profile through participation in a range of media and industry engagements, including appearances on the Manufacturer's Monthly podcast, GenUX podcast, ASX Briefs podcast, Long Shortz, and Stockhead feature articles. These engagements supported increased awareness of Optiscan's technology portfolio, commercial progress and growth strategy among industry, clinical and investor audiences.

In parallel, the Company continued to refine its communications and stakeholder engagement activities in preparation for upcoming commercial milestones, including the launch of InSpecta™ and broader commercialisation initiatives across its device portfolio.

BUSINESS OPERATIONS – LAYING THE FOUNDATION FOR GROWTH

Ensuring Optiscan has the right talent to execute on its strategic objectives remains a key focus as the Company advances its clinical and regulatory programs. During the Quarter, Optiscan hired four clinical research associates to support the upcoming Mayo Clinic studies in the U.S, including clinical study preparation, site initiation activities and engagement with key clinical stakeholders. These roles are important in supporting the clinical evidence generation required for planned U.S. FDA regulatory submissions and the Company's eventual commercialisation efforts.

During the Quarter, the Company successfully completed its ISO 13485 surveillance audit with full compliance results (zero non-conformances). This reflects the increasing maturity and effectiveness of the Company's Quality Management System and provides further confidence in Optiscan's U.S. FDA inspection readiness.

Optiscan also continued to strengthen its operational infrastructure during the Quarter, with the internalisation of key IT functions and the implementation of enhanced cybersecurity, access control, patch governance and security awareness initiatives. These improvements support the Company's expanding clinical, regulatory and commercial activities by providing a more secure, scalable and responsive technology environment for its local, remote and international teams. Together with the Company's investment in clinical capability and quality systems, these initiatives further reinforce Optiscan's operational readiness to execute upcoming clinical studies, regulatory submissions and commercial milestones.

CORPORATE UPDATE AND OUTLOOK

The June 2026 Quarter was a significant period of progress for Optiscan, marked by continued advancement across regulatory, clinical, product development, commercial and operational priorities. During the Quarter, the Company progressed preparations for its planned U.S. FDA submissions for InVue™ and InForm™, advanced multiple clinical studies, and completed key commercial launch preparations for InSpecta™ in the U.S. veterinary market.

Optiscan's clinical study programs continued to build momentum, with the Breast Cancer Study passing the halfway mark, the Head and Neck Cancer Study progressing to the next stage, and the Anatomical Pathology Study generating a broad and growing image dataset to support future regulatory and product development activities. The Company also advanced preparations for U.S.-based clinical studies with Mayo Clinic, with institutional approval received for the breast cancer clinical study and site initiation activities underway.

The Company's financial position during the Quarter was supported by the receipt of $2.537m in government grants and tax incentives, comprising a $0.843m CRC-P payment to support development of its Edge-AI-enabled gastrointestinal flexible endomicroscope and a $1.694m R&D tax refund. Optiscan also invested $1.936m in R&D during the Quarter, advancing clinical and regulatory work for the planned InVue™ and InForm™ U.S. FDA submissions, which are expected to be delivered in the second half of calendar year 2026.

As Optiscan enters the new financial year, the Company remains focused on converting its continued strong operational and clinical momentum into key regulatory and commercial milestones. The year ahead is expected to be an important period for Optiscan as it targets two planned U.S. FDA submissions, continues to build commercial traction for InSpecta™, and advances its expanding list of clinical study sites, which will soon be further bolstered by upcoming Mayo Clinic studies in the U.S.

With strong progress achieved during the Quarter, Optiscan remains well positioned to execute its regulatory, clinical and commercial priorities and looks forward to updating the market as these important milestones progress.

Note: All related party payments noted in Section 6 of the accompanying Appendix 4C during the Quarter relate to the payment of executive and non-executive director's fees, salaries and superannuation payments.

– ends –

This announcement has been authorised for release by the Board of Optiscan.

For further information, please contact:

Shareholder & General Enquiries
Optiscan Imaging Ltd
Dr Camile Farah
T: +61 3 9538 3333
E: ceo@optiscan.com

Media & Investor Enquiries
The Capital Network
Julia Maguire
T: +61 2 7257 7338
E: julia@thecapitalnetwork.com.au

About Optiscan

Optiscan Imaging Ltd (ASX: OIL) is a commercial stage medical technology company creating a suite of digital pathology and precision surgery hardware and software solutions that enable live optical biopsy for life sciences, diagnostic and surgical applications. Optiscan pioneered the development and manufacturing of miniaturised digital endomicroscopes with spatial resolution more than 1000x that of medical CT and MRI.

Using a revolutionary "tissue contact" method, Optiscan's patented technology produces super high-resolution digital pathology images for cancer diagnosis and surgical treatment, to unlock real-time insights during surgery, diagnostics, and pre-clinical research. By enabling live, non-destructive, 3D, in-vivo digital imaging at the single-cell

level, Optiscan's technology supports earlier disease detection, precision treatment, and improved patient outcomes across a wide selection of clinical applications and settings.

The global addressable market for Optiscan's medical imaging technology extends beyond traditional surgery and pathology, to also encompass the fast-growing digital health market including robotic surgery. With an expanding product suite and increased demand for digital health solutions, Optiscan is uniquely positioned to bridge the gap between surgery and pathology and deliver better outcomes for healthcare professionals and their patients.

To learn more about Optiscan, visit www.optiscan.com or follow us on LinkedIn, X or Instagram.

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate", "believe", "could", "estimate", "expect", "future", "intend", "may", "opportunity", "plan", "potential", "project", "seek", "will" and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

OPTISCAN IMAGING LIMITED

ABN	**Quarter ended ("current quarter")**
81 077 771 987	30 JUNE 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (12 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	53	723
1.2	Payments for		
	(a) research and development	(1,936)	(6,102)
	(b) product manufacturing and operating costs	(687)	(1,609)
	(c) advertising and marketing	(28)	(146)
	(d) leased assets	-	-
	(e) staff costs	(473)	(2,405)
	(f) administration and corporate costs	(238)	(708)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	163	548
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	(9)	(9)
1.7	Government grants and tax incentives	2,537	2,537
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(618)**	**(7,171)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(30)	(256)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (term deposits > 3 months maturity)	-	-
2.6	**Net cash from / (used in) investing activities**	**(30)**	**(256)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	17,751
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(112)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(45)	(152)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (payments for lease liabilities)	(78)	(249)
3.10	**Net cash from / (used in) financing activities**	**(123)**	**17,238**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	15,126	4,553
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(618)	(7,171)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(30)	(256)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(123)	17,238
4.5	Effect of movement in exchange rates on cash held	(2)	(11)
4.6	**Cash and cash equivalents at end of period**	**14,353**	**14,353**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	6,353	5,126
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (short-term deposit)	8,000	10,000
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**14,353**	**15,126**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	(175)
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

N/A

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(618)
8.2	Cash and cash equivalents at quarter end (item 4.6)	14,353
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	14,353
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	23.2[1]

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

[1] Note net cash used during the quarter was considerably lower than usual due to receipt of the R&D Rebate and CRCP grant resulting in a significant increase in estimated quarters of funding available. Using the average quarterly spend (over the last four quarters), the estimated quarters of funding available would be 6.5 quarters.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

31 July 2026

Date: .....

The Board of Directors

Authorised by: .....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.